Susceptibility of moraxella catarrhalis to 21 antimicrobial drugs: Validity of Current NCCLS criteria for the interpretation of agar disk diffusion antibiograms

Chemotherapy

Volumn 43, Issue 3, 1997, Pages 159-167

  Traub, Walter H ^a   Leonhard, Birgit ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

(Bauer Kirby) test; Agar dilution method; Agar disk diffusion; Antibiotic susceptibility; Concentration; Minimal inhibitory; Moraxella catarrhalis

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; IMIPENEM; MEROPENEM; OFLOXACIN; PENICILLIN G; RIFAMPICIN; SULBACTAM; TETRACYCLINE;

AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL;

EID: 0030887188     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239552     Document Type: Article

References (101)

1. Catlin BW: Branhamaceac lam. nov., a proposed family to accommodate the genera Branhamella and Moraxella. Int J Svst Bactcriol 1991: 41:320-323.
2. Vanccchoutte M, Verschraegen G, Claeys G, Weise B, Van den Abcele AM: Respiratory tract carrier rates of Moraxella (Branliamella) calarrhalis in adults and children and interpretation of the isolation of M. calarrhalis from sputum. J Clin Microbiol 1990;28:2674-2680.
3. Ejlertscn T: Pharyngeal carriage of Moraxella (Branliamella) calarrhalis in healthy adults. Eur J Clin Microbiol Infect Dis 1991:10:89.
4. Gotifarb P, Brauner A: Children with persistent cough - Outcome with treatment and role o(Moraxella calarrhalis? Scand J Infect Dis 1994:26:545-551.
5. Catlin BW: Branliamella calarrhalis: An organism gaining respect as a pathogen. Clin Microbiol Rev 1990; 3:293-320.
6. Berk SL: From Micrococcus Io Moraxella. The rcemcrgencc of Branlia-mella calarrhalis. Arch Intern Med 1990:150:2254-2257.
7. Anonymous: Branliamella calarrhalis: Pathogen or opportunist. Lancet 1982:i:1056.
8. Saito A, Yamaguchi K, Shigeno Y, Kohno S, Shigeno H, Kusano N, Dotsu Y, Hara K: Clinical and bacteriological evaluation of Branha-mella calarrhalis in respiratory infections. Drugs 1986:31 (suppl 3): 87-92.
9. Bluestone CD: Otitis media and sinusitis in children. Role of Branlia-mella calarrhalis. Drugs 1986: 31 (suppl 3): 132-141.
10. Christensen JJ, Gadcbcrg O, Bruun B: Branliamella calarrhalis: Significance in pulmonary infections and bacteriological features. Acta Pathol Microbiol Immunol Scand Sect B 1986:94:89-95.
11. Nicotra B, Rivera M, Luman JI, Wallace RJ Jr.,: Branhamella catarrhal is as a lower respiratory tract pathogen in patients wilh chronic lung disease. Arch Intern Med 1986: 146:890-893.
12. McLeod DT, Ahmad F, Power JT, Calder MA, Seaton A: Bronchopulmonary infection due to Branhamel-la catarrhalis. Br Med J 1983:287: 1446-1447.
13. Diamond LA, Lorber B: Branhamel-la catarrhalis pneumonia and immunoglobulin abnormalities: A new association. Am Rev Respir Dis 1984:129:876-878.
14. Slevin NJ, Aitken J, Thornley PE: Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections. Lancet 1984:i:782-783.
15. Van flare GF, Shurin PA, Marchant CD, Cartelli NA, Johnson CF, Fulton D, Carlin S, Kim CH: Acute otitis media caused by Branhamellacatarrhalis: Biology and therapy. Rev Infect Dis 1987:9:16-27.
16. Korppi M, Katila ML, Jääskeläinen J, Leinonen M: Role of Moraxella (Branhamella) catarrhalis us a respiratory' pathogen in children. Acta Paediatr 1992:81:993-996.
17. Faden H, Harabuehi Y, Hong JJ, Tonawanda/Williamsville Pediatrics: Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: Relationship to otitis media. J Infect Dis 1994:169:1312-1317.
18. Doern GV, Miller MJ, Winn RE: Branhamella (Neisseria) catarrhalis systemic disease in humans. Arch Intern Med 1981:141:1690-1692.
19. Aitken JM, Thornley PE: Isolation of Branhamella catarrhalis from sputum and tracheal aspirate. J Clin Microbiol 1983:18:1262-1263.
20. Davies BI, Macsen FPV: Branhamella catarrhalis chest infections. Lancet 1986:ii:278.
21. Johnson MA, Drew WL, Roberts M: Branhamella INeisseria) catarrhalis - A lower respiratory tract pathogen? J Clin Microbiol 1981:13: 1066-1069.
22. Lee W-S, Fordham T, Alban J: Otitis media caused by beta-lactamase-producing Branhamella (Neisseria) catarrhalis. J Clin Microbiol 1981: 13:222-223.
23. Srinivasan G, Raff MJ, Templeton WC, Givens SJ, Graves RC, Melo JC: Branhamella catarrhalis pneumonia. Report of two cases and review of the literature. Am Rev Respir Dis 1981:123:553-555.
24. Hager H, Verghese A, Alvarez S, Berk SL: Branhamella catarrhalis respiratory infections. Rev Infect Dis 1987:9:1140-1149.
25. Schonheyder H, Ejlcrtsen T: Branhamella catarrhalis in lower respiratory tract secretions in adults. Eur J Clin Microbiol Infect Dis 1989:8: 299-300.
26. Johnson AP: The pathogenic potential of commensal species of Neisseria. J Clin Pathol 1983:36:213-223.
27. Guthrie R, Bakenhaster K, Nelson R, Woskobnick R: Branhamella catarrhalis sepsis: A case report and review of the literature. J Infect Dis 1988:158:907-908.
28. Ioannidis JPA, Worthington M, Griffiths JK, Snydman DR: Spectrum and significance of bacteremia due to Mora.xella catarrhalis. Clin Infect Dis 1995:21:390-397.
29. Wiist J, Doern GV, von Graevenitz A: Branhamella catarrhalis: Fatty acid and lipopolysaccharide analysis of an atypical strain from blood culture. Diagn Microbiol Infect Dis 1988:10:131-134.
30. Wallace MR, Oldfield EC: Moraxel-la (Branhamella) catarrhalis bacteremia. Arch Intern Med 1990:150: 1332-1334.
31. Collazos J, de Miguel J, Ayarza R: Moraxella catarrhalis bactercmic pneumonia in adults: Two cases and review of the literature. Eur J Clin Microbiol Infect Dis 1992; 11:237-240.
32. Brzin B: Branhamella catarrhalis as a human pathogen and a possible hospital infectant. Zcntralbl Bakteriol 1981;A249:483-486.
33. Patterson TF, Patterson JE, Masccar BL, Barden GE, Hierholzer WJ Jr., Zervos MJ: A nosocomial outbreak of Branhamella catarrhalis confirmed by restriction endonuclease analysis. J Infect Dis 1988; 157:996-1001.
34. Picard B, Goullet P, Denamur E, Suerntondt G: Esterase electrophoresis: A molecular tool for studying the epidemiology of Branhamella catarrhalis nosocomial infection. Epidemiol Infect 1989; 103:547-554.
35. Patterson JE, Patterson TF, Farrel P, Hierholzer WJ Jr., Zervos MJ: Evaluation of restriction endonuclease analysis as an epidemiologic typing system for Branhamella catarrhalis. J Clin Microbiol 1989:27: 944-946.
36. Morgan MG, McKenzie II, Enright MC, Bain M, Emmanuel FXS: Use of molecular methods to characterize Moraxella catarrhalis strains in a suspected outbreak of nosocomial infection. Eur J Clin Microbiol Infect Dis 1992:11:305-312.
37. Hoke C, Vedros NA: Characterization of atypical aerobic gram-negative cocci isolated from humans. J Clin Microbiol 1982;15:906-914.
38. Melendez PR, Johnson RH: Bacteremia and septic arthritis caused by Moraxella catarrhalis. Rev Infect Dis 1991;13:424-429.
39. Gray LD, Van Scov RE, Anhalt JP, Yu PKW: Wound infection caused by Branhamella catarrhalis. J Clin Microbiol 1989:27:818-820.
40. McLeod DT, Ahmad F, Calder MA: Branhamella catarrhalis (beta lactamase positive) ophthalmia neonatorum. Lancet 1984;ii:647.
41. Heidemann DG, Alfonso E, Forster RK, Ullmann S, Holland SP, Mendelson A, Miller D: Branhamella ca-tarrhalis keratitis. Am J Ophthalmol 1987;103:576-581.
42. Prallet B, Lucht F, Alexandre C: Vertebral osteomyelitis due to Branhamella catarrhalis. Rev Infect Dis 1991; 13:769.
43. Doern GV, Gantz NM: Isolation of Branhamella (Neisseria) catarrhalis from men with urethritis. Sex Transm Dis 1982:9:202-204.
44. Smith GL: Branhamella catarrhalis infection imitating gonorrhea in a man. N Engl J Med 1987:316:1277.
45. Damani NN, Chin ATL: Branhamella catarrhalis peritonitis in a continuous ambulatory peritoneal dialysis patient. Nephron 1987:45: 160-161.
46. Thomlcy PH, Aitken JH, Drennan CJ, MacVicar J, Slevin NJ: Branha-mella catarrhalis infection of the lower respiratory tract: Reliable diagnosis by sputum examination. Br Med J 1982:285:1537-1538.
47. Knapp JS: Historical perspectives and identification of Neisseria and related species. Clin Microbiol Rev 1988;1:415-431.
48. Knapp JS, Rice RJ: Neisseria and Branhamella: in Murray PR. Baron EJ. Pfaller MA. Tenovcr FC. Yolken RH (eds): Manual of Clinical Microbiology, ed 6. Washington. American Society for Microbiology, 1995. pp 324-340.
49. Ahmad F, Young H, McLeod DT, Croughan MJ, Calder MA: Characterisation of Branhamella catarrhalis and differentiation from Neisseria species in a diagnostic laboratory. J Clin Pathol 1987;40:1369-1373.
50. Vanecchouette M, Verschracgen G, Claeys G, Flamen P: Rapid identification of Branhamella catarrhalis with 4-methylumbelliferyl butyratc. J Clin Microbiol 1988:26:1227-1228.
51. Louie M, Ongsansoy EG, Forward KR: Rapid identification of Branhamella catarrhalis. A comparison of five rapid methods. Diagn Microbiol Infect Dis 1990;13:205-208.
52. Spcclcveld E, Fossepre J-M, Gordls B, van Landuyt HW: Comparison of three rapid methods, tributyrine, 4-methylumbelliferyl butyrate. and in-doxyl acetate, for rapid identification of Moraxella catarrhalis. J Clin Microbiol 1994;32:1362-1363.
53. Doern GV: Branhamella catarrhalis: Phenotypic characteristics. Am J Med 1990:88(suppl 5A):33S-35S.
54. Kallings I: Sensitivity of Branhamella catarrhalis to oral antibiotics. Drugs 1986;31 (suppl 3): 17-22.
55. Calder MA, Croughan MJ, McLeod DT, Ahmad F: The incidence and antibiotic susceptibility of Branhamella catarrhalis in respiratory infections. Drugs 1986:31 (suppl 3): 11-16.
56. Sweeney KG, Vcrghcsc A, Needham CA: In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains. An-timicrob Agents Chemother 1985: 27:499-502.
57. Alvarez S, Jones M, Holtsclaw-Berk S, Guarderas J, Berk SL: In vitro susceptibilities and β-lactamasc production of 53 clinical isolates of Branhamella catarrhalis. Antimi-crob Agents Chemother 1985:27: 646-647.
58. Soto-Hernandez JL, Holtsclaw-Berk S, Harvill LM, Berk SL: Phenotypic characteristics of Branhamella catarrhalis strains. J Clin Microbiol 1989;27:903-908.
59. Fernandez-Robias R, Arricro MJ, Rodrigucz-Tudela JL, Soriano F: In-vitro activity of amoxycillin/clavu-lanic acid and five other oral antibiotics against clinical isolates of Haemophilus influenzae and Branhamella catarrhalis. J Antimicrob Chemother 1988:22:867-872.
60. Wallace RJ Jr., Nash DR, Stcingrube VA: Antibiotic susceptibility and drug resistance in Moraxella (Branhamella) catarrhalis. Ant J Med I990:88(suppl 5A):46S-50S.
61. Nash DR, Flanagan C, Steele LC, Wallace RJ Jr.: Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae. Antimicrob Agents Chemother 1991:35:192-194.
62. Ahmad F, McLeod DT, Croughan MJ, Calder MA: Antimicrobial susceptibility of Branhamella catarrhalis isolates from bronchopulmonary' infections. Antimicrob Agents Chemother 1984:26:424-425.
63. Brown BA, Wallace RJ Jr., Flanagan CW, Wilson RW, Luman JI, Redditt SD: Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother 1989;33:1631-1633.
64. Gotoh N, Tanaka S, Nishino T: Permeability of the outer membrane of Moraxella catarrhalis for β-lactam antibiotics. J Antimicrob Chemother 1992;29:279-285.
65. Forsgrcn A, Wälder M: Activity of common antibiotics against Branhamella catarrhalis. Haemophilus influenzae. pncumococci. group A streptococci and Staphylococcus aureus in 1983. Acta Otolaryngol (Stockh) 1984;suppl 407:43-49.
66. Nash DR, Wallace RJ Jr., Stcingrube VA, Shurin PA: Isoelectric focusing of β-lactamascs from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States. Drugs 1986:31 (suppl 3):48-54.
67. Percival A, Corkill JE, Rowlands J, Sykes RB: Pathogenicity of and p-lactamase production by Branhamella (Neisseria) catarrhalis. Lancet 1977;ii: 1175.
68. Ninanc G, Joly J, Kraytman M, Piot P: Bronchopulmonary infection due to p-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid. Lancet 1978:ii:257.
69. Docm GV, Siebers KG, Hallick LM, Morse SA: Antibiotic susceptibility of bcta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis. Antimicrob Agents Chemother 1980;17:24-29.
70. Doern GV, Tubcrt TA: Detection of P-lactamase activity among clinical isolates of Branhamella catarrhalis with six different P-lactamase assays. J Clin Microbiol 1987;25: 1380-1383.
71. Doern GV, Tubert TA: In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother 1988;32:259-261.
72. Nissinen A, Gronroos PO, Huovinen P, Herva E, Katila M-L, Klaukka T, Kontiaincn S, Liimatainen O, Oinoncn S, Makela PH: Development of p-lactamasc-mediated resistance to penicillin in middle-car isolates of Muraxella catarrhalis in Finnish children. 1978-1993. Clin Infect Dis 1995;21:1193-1196.
73. Labia R, Barthclemy M, Brive C, Lc Bouguennec CB, Van ABH-D: Classification of P-laelamascs from Branhamella catarrhalis in relation to penicillinases produced by other bacterial species. Drugs 1986: 31 (suppl 3):40-47.
74. Stobbcringh EE, van Eck HJ, Houben AW, van Boven CPA: Analysis of the relationship between ampicil-lin resistance and P-lactamase production in Branhamella catarrhalis. Drugs 1986:31 (suppl 3):23-27.
75. Kamme C, Eliasson I, Knutson BK, Vang M: Plasmid-mediated ß-Iacta-mase in Branliamella calarrhalis. Drugs 1986:31 (suppl 3):55-63.
76. Philippon A, Riou JY, Guibour-dcnchc M, Sotolongo F: Detection, distribution and inhibition of Branhamella calarrhalis β-lactamases. Drugs 1986;31 (suppl 3):64-69.
77. Farmer T, Reading C: Inhibition of the β-lactamases of Branhamella calarrhalis by clavulanic acid and other inhibitors. Drugs 1986:31(suppl 3):70-78.
78. Slocombe B: Inhibition of β-lacta-ntases in Branhamella calarrhalis. Drugs 1986:31 (suppl 3):79-8l.
79. Eliasson I, Kamme C: Upper respiratory tract infections. Ecological and therapeutic aspects of β-lacta-mase production with special reference to Branhamella calarrhalis. Drugs 1986,31 (suppl 3): 116-121.
80. Farmer T, Reading C: β-Lactamases of Branhamella calarrhalis and their inhibition by clavulanic acid. An-timicrob Agents Chemother 1982: 21:506-508.
81. Wallace RJ Jr., Steingrube VA, Nash DR, Hollis DG, Flanagan C, Brown BA, Labidi A, Weaver RE: BRO β-lactamases of Branhamella calarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β -lactamasc transfer by conjugation in B. calarrhalis. M. nonliquefaciens. and M. lacnnaia. Antimicrob Agents Chemother 1989;33:1845-1854.
82. Eliasson I, Kamme C, Vang M, Walcy SG: Characterization of cell-bound papain-soluble beta-lacla-mases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) calarrhalis and Moraxella nonliquefaciens. Eur J Clin Microbiol Infect Dis 1992; 11:313-321.
83. Barry AL, Fuchs PC: Susceptibility of bacterial respiratory pathogens to amoxicillin and amoxicillin-clavu-lanic acid. Eur J Clin Microbiol Infect Dis 1994:13:442-444.
84. Hol C, van Dijke EEM, Verduin CM, Verhoef J, van Dijk II: Experimental evidence for Moraxella-in-duccd penicillin neutralization in pneumococcal pneumonia. J Infect Dis 1994:170:1613-1616.
85. Christensen JJ, Keiding J, Schumacher H, Bruun B: Recognition of a new Branhamella calarrhalis β-lactamasc-BRO-3. J Antimicrob Chemother 1991;28:744-745.
86. Yokota E, Fuhii T, Sato K, Iroue M, Mitsuhashi S: Purification and properties of a ß-lactamase produced by Branhamella calarrhalis. Antimicrob Agents Chemother 1986:29:696-698.
87. Roberts MC, Brown BA, Steingrube VA, Wallace RJ Jr.: Genetic basis of tetracycline resistance in Moraxella (Branhamella) calarrhalis. Antimicrob Agents Chemother 1990;34: 1816-1818.
88. Traub WH, Leonhard B: Agar disk diffusion (Bauer-Kirby) tesis with fastidious and nonfastidious reference (ATCC) strains: Comparison of several agar media. Chemotherapy 1994;40:374-383.
89. Traub WH, Leonhard B: Antibiotic susceptibility tests with fastidious and nonfastidious bacterial reference strains: Effects of aerobic versus hypercapnie incubation. Chemotherapy 1995:41:18-32.
90. Traub WH, Leonhard B: Comparison of Wilkins-Chalgren medium supplemented with nicotinamide adenine dinucleotide and Haemophilus test medium for susceptibility testing of clinical Haemophilus isolates. Chemotherapy 1995:41:437-447.
91. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests, ed 5. NCCLS Document M2-A5. Villanova, NCCLS. 1993.
92. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 3. NCCLS Document M7-A3. Villanova. NCCLS. 1993.
93. Luman I, Wilson RW, Wallace RJ Jr. Nash DR: Disk diffusion susceptibility of Branhamella calarrhalis and relationship of β-lactam zone size to p-lactamase production. Antimicrob Agents Chemother 1986;30:774-776.
94. Doern GV, Tubert T: Disk diffusion susceptibility testing of Branhamella calarrhalis with ampicil-lin and seven other antimicrobial agents. Antimicrob Agents Chemother 1987:31:1519-1523.
95. Doern GV, Tubert T: Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella calarrhalis. J Clin Microbiol 1987:25:1576-1578.
96. Yeo SF, Livermore DM: Effect of inoculum size on the in-vitro susceptibility to β-lactant antibiotics of Moraxella calarrhalis isolates of different β-lactamase types. J Med Microbiol 1994;40:252-255.
97. Bourgault A-M, Rosenblatt JE: Characterization of anaerobic gram-negative bacilli by using rapid slide tests for β-lactamase production. J Clin Microbiol 1979:9: 654-6656.
98. Bauer AW, Kirby WMM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966:45:493-495.
99. Barry AL, Thomsberry C, Jones RN, Fuchs PC. Gavan TL, Gorbach EH: Reassessment of the ‘class' concept of disk susceptibility testing. Ccphalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. Am J Clin Pathol 1978:70:909-913.
100. Traub WH, Kohl K-H, Spohr M: In vitro activity of three fluoroquinolones against enterococci and Pseudomonas aeruginosa: Modified categorization system for discrepant broth dilution and agar disk diffusion test results. Chemotherapy 1988:34:101-106.
101. Murphy TF: Branhamella calarrhalis: Epidemiology, surface antigenic structure, and immune response. Microbiol Rev 1996:60: 267-279.